Corante

About this author
Zack Lynch is author of The Neuro Revolution: How Brain Science Is Changing Our World (St. Martin's Press, July 2009).
He is the founder and executive director of the Neurotechnology Industry Organization (NIO) and co-founder of NeuroInsights. He serves on the advisory boards of the McGovern Institute for Brain Research at MIT, the Center for Neuroeconomic Studies, Science Progress, and SocialText, a social software company. Please send newsworthy items or feedback - to Zack Lynch.
Follow me on Twitter at @neurorev
Receive by email

GUEST AUTHOR ARCHIVES
THE NEURO REVOLUTION
TNRCoverWeb120.jpg Buy on Amazon

Brain Waves

Monthly Archives

April 27, 2005

386 billion Euros - Cost of Brain Illness in Europe for 2004 - Neurotech Funding Boost Recommended

Email This Entry

Posted by Zack Lynch

Today, the European Brain Council (EBC) recommended a major boost in neurotechnology research efforts following the publication of a report stating that 127 million Europeans suffer from brain disorders, and that the financial cost of this amounted to EUR 386 billion in 2004.

The report, entitled Cost of Disorders of the Brain in Europe, focuses on the cost of the twelve most prevalent brain disorders, which include both psychiatric and neurological diseases. The costs cited involve those for healthcare, private and public expenses outside of the medical sector (for example nursing home costs), and indirect costs (restriction of work capability, absenteeism and early retirement).

1.5 billion people around the world currently suffer from a debilitating neurological or psychiatric illness. Yet, until now, no unified market-based framework was available to accelerate the development of treatments that delay, prevent and cure chronic brain-related illness.

Next week, NeuroInsights, will make available The Neurotechnology Industry 2005: A Strategic Investment and Market Analysis Report of the Global Neurological Disease and Psychiatric Illness Markets. The 250-page report provides detailed analysis of technical advancements, intellectual property trends, adoption issues and regulatory risks facing the industry. Neurotechnology companies, research centers, and venture funds are profiled and examined providing the first comprehensive view of the industry's evolving competitive landscape. For more information visit www.neuroinsights.com.


"Never doubt the power of a small group of committed individuals to change the world. It is the only thing that ever has." — Margaret Mead

Comments (0) + TrackBacks (0) | Category: Mental Health Issues

April 19, 2005

Tonight - MIT Stanford Venture Lab Tackles Neurotech

Email This Entry

Posted by Zack Lynch

For those of you in the SF/Bay Area this evening:

Don't miss tonight's MIT/Stanford Venture Lab, where Jeffrey Ostrove, CEO of Ceregene; David Mack, Director of early life science investments at Alta Partners; David Summa, President and CEO of Acumen Pharmaceuticals; Thorsten Melcher, Vice President of Discovery at Saegis Pharmaceuticals; and Frank Eeckman, Managing Editor of Centient Biotech Investor share the pitfalls and opportunities that face emerging neuropharmaceutical companies in today's investment climate.

Please join me, as I moderate this panel of experts through a discussion that will help entrepreneurs, researchers, venture investors and the general public learn how they too can tap into the booming neurotechnology market.

For those of you not able to attend, please pass this on those who might be interested.

Event Details:
Date: Tuesday, April 19, 2005
Time: 6:00 PM - Reception, Arbuckle Lounge, Stanford Business School
7:00 PM - Presentation & Discussion, Bishop Auditorium, SBS
Directions: (Click here)
Registration: (click here)

Comments (0) + TrackBacks (9) | Category: Interviews/Press

April 5, 2005

Molecules for the Mind - Tapping Into the Booming Neuropharma Market (April 19th)

Email This Entry

Posted by Zack Lynch

What challenges do entrepreneurs face in order to turn a research concept into a successful company with viable treatments?

Find out on April 19th at this month's MIT/Stanford Venture Lab, where Jeffrey Ostrove, CEO of Ceregene, discusses how they overcame scientific challenges, negotiated licensing deals, and obtained $32 million in venture financing, in their quest to develop the first gene therapy treatment for neurological disorders.

Panelist adding their perspectives to the discussion include: David Mack, Director of early life science investments at Alta Partners, David Summa, President and CEO of Acumen Pharmaceuticals, Thorsten Melcher, Vice President of Discovery at Saegis Pharmaceuticals, and Frank Eeckman, Managing Editor of Centient Biotech Investor will also be sharing their thoughts on critical pitfalls and opportunities in neuropharmaceutical discovery and development.

Please join me, as I moderate this panel of experts through a discussion that will help entrepreneurs, researchers, venture investors and the general public learn how they too can tap into the booming neurotechnology market.

Event Details:
Date: Tuesday, April 19, 2005
Time: 6:00 PM - Reception, Arbuckle Lounge, Stanford Business School
7:00 PM - Presentation & Discussion, Bishop Auditorium, SBS
Directions: (Click here)
Registration: (click here)

Comments (0) + TrackBacks (0) | Category: Neuropharma